Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase III Study of Apixaban in Patients With Atrial Fibrillation (AVERROES)
This study is ongoing, but not recruiting participants.
Study NCT00496769   Information provided by Bristol-Myers Squibb

First Received on July 2, 2007.   Last Updated on February 26, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Atrial Fibrillation
More general conditions related to this trial
Arrhythmias, Cardiac
Cardiovascular Diseases
Heart Diseases
Pathologic Processes
Interventions listed in this trial
Apixaban
Acetylsalicylic Acid (ASA)
Additional drug interventions recognized in this trial
Aspirin
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antipyretics
Antirheumatic Agents
Cardiovascular Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Bristol-Myers Squibb
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services